PortfoliosLab logo
TherapeuticsMD, Inc. (TXMD)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US88338N1072

CUSIP

88338N107

IPO Date

Dec 11, 2003

Highlights

Market Cap

$17.13M

EPS (TTM)

-$0.19

PEG Ratio

-0.73

Total Revenue (TTM)

$2.12M

Gross Profit (TTM)

$2.02M

EBITDA (TTM)

-$2.89M

Year Range

$0.70 - $2.22

Target Price

$5.00

Short %

1.07%

Short Ratio

1.95

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


TherapeuticsMD, Inc.

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period

TherapeuticsMD, Inc. (TXMD) returned 69.77% year-to-date (YTD) and -31.46% over the past 12 months. Over the past 10 years, TXMD returned -42.37% annually, underperforming the S&P 500 benchmark at 10.85%.


TXMD

YTD

69.77%

1M

17.74%

6M

2.82%

1Y

-31.46%

3Y*

-47.22%

5Y*

-51.87%

10Y*

-42.37%

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of TXMD, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202525.58%-13.89%-0.54%34.05%17.74%69.77%
20240.44%6.19%-4.58%-17.90%18.09%-27.48%8.70%7.71%-11.94%-6.63%-8.39%-39.44%-61.78%
2023-5.72%-5.88%-24.40%-5.60%17.23%-0.72%-1.46%-6.65%-20.32%-29.47%21.13%-12.79%-59.75%
2022-14.63%-21.19%58.86%-46.92%-1.54%0.20%-37.39%59.07%-33.00%-4.67%-27.65%22.05%-68.55%
202136.36%-7.88%-11.84%-9.70%0.00%-1.65%-15.97%-20.50%-6.74%-1.81%-32.01%-28.18%-70.62%
2020-7.02%-24.89%-37.28%49.06%-28.48%10.62%48.00%-21.08%8.22%-22.78%9.84%-9.70%-50.00%
201937.80%8.95%-14.86%-11.70%-28.84%-15.03%-17.31%34.42%25.61%-26.72%-5.64%-3.59%-36.48%
2018-2.65%-14.97%-2.60%12.94%7.45%5.58%-16.35%24.14%1.23%-25.46%2.86%-24.25%-36.92%
20170.69%8.09%14.65%-29.17%-18.63%26.99%7.21%6.19%-11.83%-10.78%33.47%-4.13%4.68%
2016-31.05%-14.55%4.75%28.91%8.36%-4.92%-8.59%-11.45%-1.02%-15.71%3.48%-2.86%-44.36%
2015-8.76%24.88%19.33%7.11%9.26%11.02%-0.89%-21.31%-4.40%0.17%27.94%38.08%133.03%
201426.30%4.41%-8.15%-33.44%-3.33%8.87%4.98%19.61%-16.40%-4.31%-13.51%15.89%-14.59%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of TXMD is 35, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of TXMD is 3535
Overall Rank
The Sharpe Ratio Rank of TXMD is 3434
Sharpe Ratio Rank
The Sortino Ratio Rank of TXMD is 4040
Sortino Ratio Rank
The Omega Ratio Rank of TXMD is 4040
Omega Ratio Rank
The Calmar Ratio Rank of TXMD is 2929
Calmar Ratio Rank
The Martin Ratio Rank of TXMD is 3030
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for TherapeuticsMD, Inc. (TXMD) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

TherapeuticsMD, Inc. Sharpe ratios as of May 31, 2025 (values are recalculated daily):

  • 1-Year: -0.29
  • 5-Year: -0.27
  • 10-Year: -0.29
  • All Time: -0.12

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of TherapeuticsMD, Inc. compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


TherapeuticsMD, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the TherapeuticsMD, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the TherapeuticsMD, Inc. was 99.99%, occurring on Mar 14, 2025. The portfolio has not yet recovered.

The current TherapeuticsMD, Inc. drawdown is 99.98%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-99.99%Feb 3, 20103484Mar 14, 2025
-86.67%Aug 24, 20091Aug 24, 200950Dec 8, 200951
-53.64%Feb 26, 20094Jun 15, 20093Jul 21, 20097
-37.11%Jan 25, 20102Jan 26, 20105Feb 2, 20107
-29.03%Dec 15, 200910Dec 30, 200910Jan 22, 201020
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of TherapeuticsMD, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of TherapeuticsMD, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -355.3%.


-10.00-5.000.005.0010.0020212022202320242025
0.02
0.03
Actual
Estimate

Valuation

The Valuation section provides an overview of how TherapeuticsMD, Inc. is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for TXMD compared to other companies in the Drug Manufacturers - Specialty & Generic industry. TXMD currently has a PEG ratio of -0.7. This PEG ratio is negative, which typically signals that the company's earnings are expected to decline. A negative PEG is not considered meaningful for valuation purposes.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for TXMD relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TXMD has a P/S ratio of 9.3. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for TXMD in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, TXMD has a P/B value of 0.6. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items